AFC-HD AMS Life Science Co., Ltd. (TYO:2927)
Japan · Delayed Price · Currency is JPY 887.00
+2.00 (0.23%)
Jul 22, 2025, 3:30 PM JST
AFC-HD AMS Life Science Income Statement
Financials in millions JPY. Fiscal year is September - August.
Millions JPY. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | May '25 May 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 | Aug '20 Aug 31, 2020 | 2015 - 2019 |
| 32,578 | 30,185 | 25,579 | 22,997 | 22,368 | 15,819 | Upgrade | |
Revenue Growth (YoY) | 11.46% | 18.01% | 11.23% | 2.81% | 41.40% | -2.66% | Upgrade |
Cost of Revenue | 21,459 | 19,694 | 16,256 | 14,418 | 15,503 | 11,265 | Upgrade |
Gross Profit | 11,119 | 10,491 | 9,323 | 8,579 | 6,865 | 4,554 | Upgrade |
Selling, General & Admin | 8,620 | 8,349 | 7,526 | 7,415 | 4,580 | 3,419 | Upgrade |
Other Operating Expenses | - | - | - | - | 1 | - | Upgrade |
Operating Expenses | 8,846 | 8,575 | 7,686 | 7,567 | 4,619 | 3,460 | Upgrade |
Operating Income | 2,273 | 1,916 | 1,637 | 1,012 | 2,246 | 1,094 | Upgrade |
Interest Expense | -175 | -101 | -57 | -57 | -50 | -32 | Upgrade |
Interest & Investment Income | 16 | 10 | 16 | 16 | 15 | 17 | Upgrade |
Other Non Operating Income (Expenses) | 145 | 11 | 21 | 356 | -46 | 16 | Upgrade |
EBT Excluding Unusual Items | 2,259 | 1,836 | 1,617 | 1,327 | 2,165 | 1,095 | Upgrade |
Gain (Loss) on Sale of Investments | 2 | 69 | 36 | 11 | -4 | -32 | Upgrade |
Gain (Loss) on Sale of Assets | 37 | 38 | - | - | - | - | Upgrade |
Asset Writedown | -21 | -15 | -31 | -88 | -3 | -9 | Upgrade |
Other Unusual Items | 265 | -17 | -77 | -16 | -1 | -51 | Upgrade |
Pretax Income | 2,542 | 1,911 | 1,545 | 1,234 | 2,157 | 1,003 | Upgrade |
Income Tax Expense | 748 | 665 | 439 | 497 | 662 | 327 | Upgrade |
Earnings From Continuing Operations | 1,794 | 1,246 | 1,106 | 737 | 1,495 | 676 | Upgrade |
Minority Interest in Earnings | -52 | 6 | -4 | -2 | - | - | Upgrade |
Net Income | 1,742 | 1,252 | 1,102 | 735 | 1,495 | 676 | Upgrade |
Net Income to Common | 1,742 | 1,252 | 1,102 | 735 | 1,495 | 676 | Upgrade |
Net Income Growth | 29.81% | 13.61% | 49.93% | -50.84% | 121.15% | -13.66% | Upgrade |
Shares Outstanding (Basic) | 14 | 14 | 14 | 14 | 14 | 14 | Upgrade |
Shares Outstanding (Diluted) | 14 | 14 | 14 | 14 | 14 | 14 | Upgrade |
Shares Change (YoY) | 0.22% | -0.01% | -0.47% | 0.36% | 0.04% | - | Upgrade |
EPS (Basic) | 123.85 | 89.19 | 78.47 | 52.31 | 107.08 | 48.07 | Upgrade |
EPS (Diluted) | 123.78 | 89.11 | 78.46 | 52.08 | 106.30 | 48.07 | Upgrade |
EPS Growth | 29.35% | 13.57% | 50.65% | -51.01% | 121.15% | -13.66% | Upgrade |
Free Cash Flow | - | -1,866 | -1,074 | 535 | 2,091 | 918 | Upgrade |
Free Cash Flow Per Share | - | -132.80 | -76.43 | 37.89 | 148.62 | 65.27 | Upgrade |
Dividend Per Share | 31.000 | 30.000 | 27.500 | 30.000 | 27.500 | 20.000 | Upgrade |
Dividend Growth | 3.33% | 9.09% | -8.33% | 9.09% | 37.50% | - | Upgrade |
Gross Margin | 34.13% | 34.76% | 36.45% | 37.30% | 30.69% | 28.79% | Upgrade |
Operating Margin | 6.98% | 6.35% | 6.40% | 4.40% | 10.04% | 6.92% | Upgrade |
Profit Margin | 5.35% | 4.15% | 4.31% | 3.20% | 6.68% | 4.27% | Upgrade |
Free Cash Flow Margin | - | -6.18% | -4.20% | 2.33% | 9.35% | 5.80% | Upgrade |
EBITDA | 3,433 | 3,000 | 2,620 | 2,017 | 2,894 | 1,602 | Upgrade |
EBITDA Margin | 10.54% | 9.94% | 10.24% | 8.77% | 12.94% | 10.13% | Upgrade |
D&A For EBITDA | 1,160 | 1,084 | 983 | 1,005 | 648 | 508 | Upgrade |
EBIT | 2,273 | 1,916 | 1,637 | 1,012 | 2,246 | 1,094 | Upgrade |
EBIT Margin | 6.98% | 6.35% | 6.40% | 4.40% | 10.04% | 6.92% | Upgrade |
Effective Tax Rate | 29.43% | 34.80% | 28.41% | 40.28% | 30.69% | 32.60% | Upgrade |
Advertising Expenses | - | 687 | 748 | 736 | 504 | 438 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.